Custom Protein Science Services
Why ARVYS

Expertise in Protein Technologies

GET ARVYS EXPERTISE

  • We integrate our expertise in protein technologies for each project to ensure project's success.
  • We can monitor activity and stability of proteins during purification procedures thus minimizing presence of aggregated or denatured target protein in your preparations.
  • Our instrumentation and experience allow us to develop a variety of biochemical and biophysical assays and use them for protein, peptide, and small molecule characterization.
  • We reduce your cost by maximizing the activity and stability of your protein product.
  • We deliver endotoxin-free active proteins for your in vivo studies.


WHY DO YOU NEED EXPERT HELP TO PURIFY AND CHARACTERIZE PROTEINS?

Your protein which appears as a single protein band on SDS-PAGE could be heterogeneous due to:
  • Aggregated, modified or partially degraded forms of the target protein
  • Other proteins with the same rate of migration on SDS-PAGE
  • Products from faster growing cells which may come from incomplete clonal selection or clone modification
  • Presence of highly active impurities which are not easily visualized, such as endotoxin

Heterogeneity in preparations results in the following problems:
  • Presence of even small amounts of denatured or misfolded proteins may trigger further protein denaturation leading to instability during manipulations and storage 
  • Small impurities may contribute disproportionately to the product concentration measurements resulting in erroneous data interpretation.
  • In in vivo studies, denatured protein, contaminants and endotoxin may induce unwanted biological responses
  • In screening experiments, denatured protein may bind inhibitors and significantly affect Ki and IC50 values

Your protein preparation may be fully or partially inactive due to:
  • Failure to form a native conformation during production or renaturation procedures
  • Denaturation, degradation or modification
  • Alteration by protein tagging or labeling
  • Shielding of an active site by contaminating ligands

Loss or alteration of functional activity results in the following problems:
  • Ligand binding parameters are changed
  • Larger amounts of protein have to be used
  • Result consistency may be affected
  • Increased contribution from background activity reduces assay window
  • Biological responses are too low to be measured
  • Your protein preparation may generate inconsistent and unreliable data.
Why ARVYS

About Us

WE HAVE BEEN IN CUSTOM PROTEIN SERVICES BUSINESS SINCE 2005 BECAUSE:

  • We offer reliable services that are fully aligned with client’s goals and expectations.
  • Our products are of high quality. Our results are above expectations.
  • No one handles difficult protein projects better. It is our specialty.
  • We respond promptly to emails, phone calls, are easily available for web or on-site meetings.
  • We take ownership for every project. We go an extra mile to assure its success.
  • We perform every project with the sense of urgency. We strive to deliver on time.

SELECTED LIST OF SCIENTIFIC PUBLICATIONS ACKNOWLEDGING US AS A SERVICE PROVIDER:

NATURE, 2010, 467 (7311): 95-8.
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.
He G1, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP, Greengard P.
1Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA.

BIOCHEMISTRY, 2013, 52 (45):8165–8176.
G/U and Certain Wobble Position Mismatches as Possible Main Causes of Amino Acid Misincorporations.
Zhongqi Zhang, Bhavana Shah, and Pavel V. Bondarenko.
Process and Product Development, Amgen Inc., Thousand Oaks, CA 91320, USA.

THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (23): 16529–16537.
Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of Biotherapeutics.
Tetsuya Ishino‡1, Mengmeng Wang§, Lidia Mosyak‡, Amy Tam‡, Weili Duan‡, Kristine Svenson‡, Alison Joyce§, Denise M. O’Hara§, Laura Lin‡, William S. Somers‡, and Ronald Kriz‡.
‡Global Biotherapeutics Technologies, Pfizer Inc., Cambridge, MA 02140, USA.
§Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Andover, MA 01810, USA.

THE JOURNAL OF IMMUNOLOGY, 2015 (195): 621-631.
Tick Salivary Sialostatin L Represses the Initiation of Immune Responses by Targeting IRF4-Dependent Transcription in Murine Mast Cells.
Klein M1, Brühl TJ1, Staudt V1, Reuter S2, Grebe N1, Gerlitzki B1, Hoffmann M1, Bohn T1, Ulges A1, Stergiou N1, de Graaf J3, Löwer M3, Taube C4, Becker M1, Hain T1, Dietzen S1, Stassen M1, Huber M5, Lohoff M5, Campos Chagas A6, Andersen J6, Kotál J7, Langhansová H8, Kopecký J8, Schild H1, Kotsyfakis M7, Schmitt E1, Bopp T9.
1Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
2III. Medical Clinic, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
3Translational Oncology, University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
4Department of Pulmonology, Leiden University Medical Center, 2333 ZA Leiden, the Netherlands.
5Institut für Medizinische Mikrobiologie und Krankenhaushygiene, 35043 Marburg, Germany.
6Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852;USA.
7Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic.
8Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, 37005 České Budějovice, Czech Republic; and Faculty of Science, University of South Bohemia, 37005 České Budějovice, Czech Republic.
9Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.

CANCER IMMUNOLOGY RESEARCH, 2015, 3(7): 787–94.
The Epstein–Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development. Alex S. Hartlage, Tom Liu, John T. Patton, Sabrina L. Garman, Xiaoli Zhang, Habibe Kurt, Gerard Lozanski, Mark E. Lustberg, Michael A. Caligiuri and Robert A. Baiocchi.
The Ohio State University, Columbus, OH, USA

EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 71(8): 1145–1155.
Identification and characterization of DC-SIGN-binding glycoproteins in allergenic foods.
M. Kamalakannan1, L. M. Chang1, G. Grishina1, H. A. Sampson1,2 & M. Masilamani1,2.
1Division of Allergy and Immunology, Department of Pediatrics, The Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai;
2Immunology Institute and The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

NATURE/SCIENTIFIC REPORTS, 2017 (7): 42880.
Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.
Alessandra Bonito-Oliva1, Shahar Barbash1, Thomas P. Sakmar1,2 & W Vallen Graham1
1 Laboratory of Chemical Biology & Signal Transduction, The Rockefeller University, New York, NY 10065, USA.
2 Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, 141 57 Huddinge, Sweden.


 

MEET OUR PRESIDENT

YELENA SHEPTOVITSKY, PH.D., M.B.A
E-mail: ysheptovitsky@arvysproteins.com 
Phone: 203.304.2495 ext. 3#

Dr. Sheptovitsky has over 30 years of R&D experience working with biologics. Her areas of expertise include gene-to-protein production, purification of native proteins from natural sources including integral membrane proteins, protein characterization, assays & assay development, protein labeling & conjugation, endotoxin removal, antigen & antibody development. In addition, she has prior scientific background in physical chemistry, catalysis and metal coordination chemistry. Dr. Sheptovitsky has M.S. in Chemistry from Moscow State University by M.V. Lomonosov, Ph.D. in Biochemistry from Yale University, M.B.A. from University of Connecticut. She conducted her post-doctoral training at Memorial Sloan-Kettering Cancer Center. Dr. Sheptovitsky had been with ARVYS Proteins Inc. from its inception in 2005.